Literature DB >> 28368889

Image of the Month: Multifocal 68Ga Prostate-Specific Membrane Antigen Ligand Uptake in the Skeleton in a Man With Both Prostate Cancer and Multiple Myeloma.

Isabel Rauscher1, Tobias Maurer, Katja Steiger, Markus Schwaiger, Matthias Eiber.   

Abstract

Ga prostate-specific membrane antigen (PSMA) HBED-CC PET/CT in a 65-year-old man with first diagnosis of prostate cancer (PC) and a history of multiple myeloma showing multifocal PSMA ligand uptake in the skeleton with corresponding osteolytic lesions in CT. Although osteolytic bone metastases are very rare in PC, PSMA expression in PET raised the suspicion of PC bone metastases. Bone marrow biopsy excluded PC metastases with immunohistochemistry showing endothelial expression of PSMA in small vessels within the myeloma.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28368889     DOI: 10.1097/RLU.0000000000001649

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  9 in total

1.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

Review 2.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

Review 3.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236

4.  Metastatic prostate cancer with bone marrow infiltration mimicking multiple myeloma.

Authors:  Pankaj Mathur; Daisy Alapat; Manoj Kumar; Sharmilan Thanendrarajan
Journal:  Clin Case Rep       Date:  2017-12-22

5.  The meta-analysis of the effect of 68Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan.

Authors:  Ruining Zhao; Yajie Li; Lihong Nie; Kaiyue Qin; Hang Zhang; Hongbin Shi
Journal:  Medicine (Baltimore)       Date:  2021-04-16       Impact factor: 1.817

6.  Non-prostate uptake on 18F-PSMA-1007 PET/CT: a case of myeloma.

Authors:  Sowmya Veerasuri; Stewart Redman; Richard Graham; Chris Meehan; David Little
Journal:  BJR Case Rep       Date:  2020-11-03

7.  Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy.

Authors:  Jonathan Miksch; Dirk Bottke; Thomas Krohn; Reinhard Thamm; Detlef Bartkowiak; Christoph Solbach; Christian Bolenz; Meinrad Beer; Thomas Wiegel; Ambros J Beer; Vikas Prasad
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03-10       Impact factor: 9.236

8.  Nonspecific Uptake of 68Ga-Prostate-Specific Membrane Antigen in Diseases other than Prostate Malignancy on Positron Emission Tomography/Computed Tomography Imaging: A Pictorial Assay and Review of Literature.

Authors:  Dharmender Malik; Apurva Sood; Bhagwant Rai Mittal; Harmandeep Singh; Rajender Kumar Basher; Jaya Shukla; Anish Bhattacharya; Shrawan Kumar Singh
Journal:  Indian J Nucl Med       Date:  2018 Oct-Dec

9.  Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on 18F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression.

Authors:  Lena M Mittlmeier; Stephan T Ledderose; Melanie Schott; Matthias Brendel; Leonie Beyer; Sebastian Theurich; Doris Mayr; Christoph Walz; Wolfgang G Kunz; Jens Ricke; Peter Bartenstein; Harun Ilhan; Michael Staehler; Marcus Unterrainer
Journal:  Diagnostics (Basel)       Date:  2021-03-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.